We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

233 hedge funds and large institutions have $1.24B invested in BioCryst Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 101 increasing their positions, 57 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

287% more call options, than puts

Call options by funds: $22.4M | Put options by funds: $5.79M

77% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 57

1% more capital invested

Capital invested by funds: $1.23B → $1.24B (+$18.3M)

0.61% more ownership

Funds ownership: 92.14% → 92.75% (+0.61%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

5% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 22

1% less funds holding

Funds holding: 236 → 233 (-3)

Holders
233
Holders Change
-3
Holders Change %
-1.27%
% of All Funds
3.7%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
21
Increased
101
Reduced
57
Closed
22
Calls
$22.4M
Puts
$5.79M
Net Calls
+$16.6M
Net Calls Change
+$3.11M

Top Buyers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
+$18.5M
2
DM
Deerfield Management
New York
+$14.1M
3
N
Nuveen
North Carolina
+$11.3M
4
BlackRock
BlackRock
New York
+$9.19M
5
Morgan Stanley
Morgan Stanley
New York
+$6.87M

Top Sellers

Rank Fund Capital Flow
1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$30.3M
2
State Street
State Street
Massachusetts
-$12.9M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8.95M
4
Fisher Asset Management
Fisher Asset Management
Washington
-$8.19M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$4.93M
Name Holding Trade Value Shares
Change 		Change in
Stake
MIM
101
MetLife Investment Management
New Jersey
$689K – – –
AIG
102
American International Group
New York
$670K +$24.2K +3,364 +4%
Tudor Investment Corp
103
Tudor Investment Corp
Connecticut
$669K +$128K +17,773 +23%
Ensign Peak Advisors
104
Ensign Peak Advisors
Utah
$657K – – –
DA
105
Doliver Advisors
Texas
$573K – – –
Janus Henderson Group
106
Janus Henderson Group
United Kingdom
$569K +$50 +7 +0%
BCM
107
Bayesian Capital Management
New York
$557K +$458K +63,700 +425%
New York State Common Retirement Fund
108
New York State Common Retirement Fund
New York
$544K +$104K +14,498 +23%
DekaBank Deutsche Girozentrale
109
DekaBank Deutsche Girozentrale
Germany
$532K – – –
GC
110
Grimes & Company
Massachusetts
$521K +$6.49K +903 +1%
AQR Capital Management
111
AQR Capital Management
Connecticut
$521K +$255K +35,429 +93%
GAM
112
Gotham Asset Management
New York
$489K +$496K +69,033 New
EGM
113
Engineers Gate Manager
New York
$474K +$237K +33,000 +97%
PCS
114
Personal CFO Solutions
New Jersey
$473K – – –
Hudson Bay Capital Management
115
Hudson Bay Capital Management
Connecticut
$460K +$2.15K +300 +0.5%
ACM
116
Aquatic Capital Management
Illinois
$457K +$257K +35,800 +124%
QT
117
Quantbot Technologies
New York
$454K +$461K +64,100 New
Canada Life
118
Canada Life
Manitoba, Canada
$439K +$145K +20,213 +48%
NFC
119
Northeast Financial Consultants
Connecticut
$429K – – –
FSA
120
Franklin Street Advisors
North Carolina
$425K +$71.8K +10,000 +20%
Royal Bank of Canada
121
Royal Bank of Canada
Ontario, Canada
$408K +$96.3K +13,397 +30%
BRA
122
Bender Robert & Associates
California
$401K -$86.2K -12,000 -17%
State Board of Administration of Florida Retirement System
123
State Board of Administration of Florida Retirement System
Florida
$399K +$647 +90 +0.2%
ASRS
124
Arizona State Retirement System
Arizona
$381K +$6.2K +863 +2%
Teacher Retirement System of Texas
125
Teacher Retirement System of Texas
Texas
$380K +$18.1K +2,519 +5%
3 4
5
6 7

BCRX Hedge Fund Activity: Q3 2023 in Review

233 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2023, worth a combined $1.24B — up 1.5% from $1.23B a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of BCRX and 21 opened new positions — a net loss of 1 holder — while 57 trimmed existing stakes and 101 added.

The largest buyer was Braidwell, adding an estimated $18.5M. The largest seller was Assenagon Asset Management, cutting an estimated $30.3M.

  • 233 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2023, down from 236 in Q2 2023.
  • Funds reported $1.24B of BioCryst Pharmaceuticals stock for Q3 2023, up 1.5% quarter-over-quarter.
  • 21 funds opened new BioCryst Pharmaceuticals positions in Q3 2023 and 22 closed out, a net change of -1 holder.
  • The largest BioCryst Pharmaceuticals buyer in Q3 2023 was Braidwell, an estimated $18.5M added.
  • The largest BioCryst Pharmaceuticals seller in Q3 2023 was Assenagon Asset Management, an estimated $30.3M sold.

Based on aggregated 13F filings for Q3 2023.